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Abstract 
 
Objective(s) 
Theophylline, a xanthenes derivative, is still widely used as an effective bronchodilator in the management 
of asthmatic patients. It is used both as a prophylactic drug and to prevent acute exacerbations of asthma. 
The aim of study was to formulate and evaluate effect of the microencapsulation of theophylline loaded 
nanoparticles on the reduction of burst release. 
Materials and Methods 
Microparticles (simple and composite) and nanoparticles were prepared by using water-in-oil-in-water 
(W1/O/W2 double-emulsion solvent diffusion/evaporation method), taking different ratios of drug/polymer. 
Solvent systems consist of ethyl acetate and dichloromethane for microspheres and nanospheres, 
respectively. In the current study formulations were characterized by loading efficiency, yield, particle size, 
zeta potential, X-ray diffraction (XRD) and differential scanning calorimetry (DSC). 
Results 
In microparticles, the best drug to polymer ratio was 0.8:1 (F3). F3 formulation had minimum burst effect 
(37.81%), high loading efficiency  (95.88%). In nanoparticles, F4 formulation (0.4:1 drug/polymer ratio) 
showed high production yield (40.8%), loading efficiency (99.05%), low particle size (756 nm) and 
minimum burst effect compared with other nanoparticle formulations. The drug loaded composite 
microspheres (F9) showed minimum burst effect, acceptable release and mean particle size 17.696 µm. The 
XRD and DSC showed stable character of theophylline in the drug loaded microspheres. The drug release 
was found to be diffusion and erosion controlled. 
Conclusion 
The burst was significantly lower with composite microparticles and may be explained by lower diffusion of 
the drug from double polymeric wall formed by the nanoparticles matrix followed by another diffusion step 
through the microparticle polymeric wall.   
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Introduction 
Theophylline, a xanthine derivative, is still 
widely used as an effective bronchodilator in 
the management of asthmatic patients. It is used 
both as a prophylactic drug and to prevent acute 
exacerbations of asthma (1, 2). A popular 
method for the encapsulation of water-soluble 
drugs within water insoluble polymers is the 
double-emulsion solvent evaporation method 
(3). The water-soluble drug is dissolved in 
water and this solution is emulsified in an 
organic solution of the polymer to be used for 
the wall material. This primary emulsion is then 
emulsified  in  an  aqueous  phase  to  form  a             
W/O/W emulsion. After evaporation of organic 
solvent an aqueous suspension of microparticles 
is produced. However, most of the 
microencapsulation techniques have been used 
for lipophilic drugs, since hydrophilic drugs 
showed low loading efficiencies. Other workers 
have used water in oil in water (W/O/W) 
emulsification in the solvent evaporation 
process to encapsulate highly water-soluble 
drugs (3, 4). A further effect of partitioning is 
the accumulation of drug crystals on the surface 
of microspheres which produces burst release of 
the drug on administration (5, 6). One major 
persistent problem in the development of 
commonly marketed injectable polymeric 
delivery systems is the burst release of drug 
when slow release is needed for some weeks 
or months. First burst release is one of critical 
problems in the improvement of controlled 
release formulations containing drug 
entrapment microparticles and nanoparticles, 
particularly with low molecular weight drugs.  
Hassan  et al (7) and Lee et al (8) have 
suggested that encapsulation of nanoparticles 
into polymeric microparticles is a way to 
reduce the burst. This burst release, is useful 
in the drug permeation within dermal 
applications, but is a disadvantage for slow 
release formulations with drugs that are toxic 
at high strengths or those that require being 
released for a long time. Burst release is 
frequently resulted in polymeric delivery 
systems, it is not predictable and usually hard 
to control, but can be stopped by altering the 
drug dispersion in the polymer matrix (9) or 
by improving more complicated drug delivery 
systems. Recent results show that liposoms 
encapsulated in dextran (10) and alginate 
microcapsules enable the controlled drug 
release and removing the burst release (11). 
Double-walled microspheres (12), double-
layered minipellets (13) and coated 
microspheres (14, 15) have developed to 
decrease the initial burst and supply drug 
prolonged release models. Microparticles 
prepared with blends of polymers characterized 
by different properties may also modify the 
release of the drug compared with 
microparticles prepared from a single polymer. 
For  ibuprofen,  the  burst  was  higher                     
for ethylcellulose microparticles than 
microparticles prepared with a blend of 
ethylcellulose and polystyrene when they were 
compared (16). Currently, the encapsulation of 
hydrophilic drug inside biodegradable polymer 
as poly (-є-caprolactone)-based were improved 
by using solvent evaporation methods (17). The 
use of poly-є-caprolactone (PCL), aliphatic 
semi-crystalline polyester, has been resulted in 
controlled drug release. When caprolactone was 
used alone led to the controlled release of the 
drug encapsulated for more than a month (18). 
However, the degree of degradation of PCL will 
generally depend upon the nature of the 
polymer (hydrophobicity and semi-crystalline 
type), and is more than polymers based on poly 
(lactic acid) (PLA) derivatives. The degradation 
of this polymer (PCL) includes a bulk erosion 
procedure (19-20). 
Size and release properties of microspheres 
are the key considerations to design suitable 
microsphere delivery systems (5). Since the 
release kinetics of drug dominantly depends on 
polymer nature, the physical states of the 
polymer and drug (e.g. crystalline, amorphous, 
glassy, rubbery, and molecularly dispersed) are 
of major importance for underlying drug release 
mechanism (1, 17). Morphology and drug 
distribution within microspheres, fundamental 
understanding of the relationship among these 
key characteristics and release mechanisms are 
essential to yield useful products (21). For 
example, within an amorphous polymer the 
diffusion coefficient of a drug is much higher 
compared to that within a crystalline polymer 
(1, 17).   
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The aim of the present work was to 
encapsulate, using the W/O/W emulsion 
method, polymeric nanoparticles into 
polymeric microparticles by biodegradable 
polymer, poly (-ε-caprolactone)-based  
microparticles and water insoluble polymer 
(ethylcellulose). In addition, drug crystallinity 
in the microspheres, interaction between drug 
and polymer were evaluated by powder X-ray 
diffraction analysis (XRD) and differential 
scanning calorimetry (DSC), respectively. 
 
Materials and Methods  
Materials 
Theophylline  (Merck,  Germany),  poly             
(ε-caprolactone) (MW 40,000 Da) was supplied 
by Aldrich, USA. An acrylic polycationic 
nonbiodegradable polymer (copolymers of 
acrylic acid esters with a low content of 
quaternary ammonium groups (o.5-0.8%)       
(4.48-6.77% ammonium methacrylate units by 
dry weight), poly (vinyl alcohol) (PVA) (MW 
95000-110000 Da) was supplied by Aldrich, 
USA, ethylcellulose powder (viscosity 7 Cp) 
(Aldrich, USA), ethyl acetate, methylene 
chloride, hydrochloric acid, potassium 
hydrogen phosphate and sodium hydroxide 
were obtained from Merck (Darmstadt, 
Germany). All solvents and reagents were of 
analytical grade.  
 
Experimental Methods 
Preparation of particles (classical 
microparticle) 
Theophylline-loaded ethylcellulose microparticles 
were prepared by the W1/O/W2 emulsion solvent 
extraction method, using different ratios of drug 
to polymer (0.4:1, 0.6: 1 and 0.8: 1 as shown in 
Table 1) (8, 9). In the first step, an aqueous 
solution (1 ml) of drug used as the internal 
aqueous phase was emulsified into an organic 
solution of the polymer (ethylcellulose 250 mg) 
in ethyl acetate (5 ml) by homogenizer with 
22000 rpm. At 2 min later, the primary emulsion 
was poured into 20 ml of 0.1% PVA aqueous 
solution in order to obtain a W1/O/W2 pre-
emulsion. After magnetically stirring for 1 min 
(1000 rpm) at room temperature, this pre-
emulsion was added to 400 ml of a 0.1% PVA 
aqueous solution and stirred mechanically (three-
blended propeller, 1600 rpm) for 10 min to form 
the final W1/O/W2 emulsion and allow 
microparticle hardening. Upon solvent 
extraction, the polymer precipitated and 
microparticle cores were solidified. 
Microparticles were collected by vacuum 
filtration (Heidolph, USA) and freeze-drying (9). 
Blank microparticles were prepared under the 
same conditions, without drug. 
 
Preparation of nanoparticles (NP) 
Theophylline -loaded PCL and ethylcellulose 
microparticles were prepared by the W1/O/W2 
solvent evaporation method taking different 
ratios  of  drug  to  polymer  (0.4:1,  0.6:  1             
and 0.8: 1 as shown in Table 2). Briefly, 1 ml 
of  aqueous  internal  phase  was  emulsified              
for 15 sec in 5 ml of methylene chloride 
(containing 125 mg of PCL and 125 mg 
ethylcellulose) using homogenizer with     
22000 rpm. This primary emulsion was 
poured into 40 ml of a 0.1% PVA aqueous 
solution while stirring using a homogenizer 
for  1  min  under  the  same  conditions               
in order to create the water-in-oil-in-water 
emulsion. Three to four ml of NP suspension             
was  obtained  after  solvent  evaporation           
under reduced pressure (Evaporator, 
Heidolph, USA). Nanoparticles were separated 
from the bulk suspension by centrifugation 
(Hettich universal 320R, USA) at 42,000×g for 
20 min. The supernatant was kept for drug 
assay as described later and the sediment 
 
 
Table 1. Theophylline polymeric microspheres prepared by double-emulsion solvent extraction (W1/O/W2). 
 
Initial emulsion 
 (W1/O) 
Secondary aqueous phase 
(W2 ) 
Initial aqueous 
phase (W1) 
Organic phase 
 (O) 
Formulations 
 
Drug/ 
Polymer 
ratios 
Water 
(ml) 
Theophylline 
(mg) 
Ethylcellulose 
(mg) 
Ethyl acetate 
(ml) 
Polyvinyl alcohol (0.1%) 
(ml) 
F1 
F2 
F3 
0.4:1 
0.6:1 
0.8:1 
1 
1 
1 
100 
150 
200 
250 
250 
250 
5 
5 
5 
420 
420 
420  
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nanoparticles were redispersed in 3 ml of 
purified water before freeze-drying. After 
lyophilization, the dried nanoparticles were 
resuspended in 2 ml of purified water shortly 
before preparing the composite microparticles. 
Blank nanoparticles were prepared under the 
same conditions, without drug (8, 22). 
 
Preparation of composite microparticle 
Microparticles containing theophylline PCL 
and ethylcellulose nanoparticles, called 
composite microparticles were prepared under 
the same conditions of simple microparticles 
preparation method, but in primary emulsion 
(W1/O): PCL and ethylcelulose NP suspension 
(2 ml) used as the internal aqueous phase 
(instead of 2 ml of drug aqueous solution) was 
emulsified in an organic solution of polymer in 
ethyl acetate. Blank composite microparticles 
were prepared under the same conditions 
without drug (8). 
 
Viscosity measurement 
A Brookfield rotational digital viscometer 
DVLV-II was used to measure the viscosity 
(cPs) of the internal and external phases at 25 ºC. 
The spindle number 1was rotated at 100 rpm.  
 
Particle size analysis  
A laser light scattering particle size analyzer 
(SALD-2101, Shimadzu, Japan) was used to 
determine the particle size of the drug, 
nanoparticles and microparticle formulations. 
Samples were suspended in distilled water 
contained in a 1 cm cuvette and stirred 
continuously during the particle size analysis. 
Each sample was measured in triplicate. 
Zeta potential analysis 
Zeta potential is an abbreviation for 
electrokinetic potential in colloidal systems. 
Zeta potential is electric potential in the 
interfacial double layer (DL) at the location of 
the slipping plane versus a point in the bulk 
fluid away from the interface (22). 
 
Determination of drug loading, loading 
efficiency (%) and production yield 
The drug concentration in polymeric particles 
was  determined  spectrophotometrically        
(UV-160, Shimadzu, Japan) at 271.6 nm by 
measuring the amount of non-entrapped 
theophylline in the external aqueous solution 
(indirect method) before freeze-drying. In the 
case of nanoparticles, the external aqueous 
solution was obtained after centrifugation of the 
colloidal suspension for 20 min at 42,000×g. A 
standard calibration curve was performed with 
the theophylline solution (aqueous solution of 
0.1% PVA).  
The loading efficiency (%) was calculated 
according to the following equation: 
Loading efficiency (%) = (actual drug content in 
microparticles/theoretical drug content)× 100 
  The production yield of the microparticles 
was determined by calculating accurately the 
initial weight of the raw materials and the last 
weight of the polymeric particles obtained. All 
the experiments were performed in triplicate. 
 
X-ray powder diffractometry (X-RPD) 
X-ray diffraction analysis was performed with 
an apparatus (Siemens D5000, Munich, 
Germany), using nickel-filtered CuKα radiation 
radiation (a voltage of 40 KV and a current of
 
 
 
Table 2. Theophylline nanoparticle formulations prepared by double-emulsion solvent evaporation method (W1/O/W2). 
Initial emulsion (W1/O) 
Secondary 
aqueous 
phase 
(W2 ) 
Initial aqueous 
phase (W1)  Organic phase (O) 
Formulations 
 
Drug/polymer 
ratio 
Water 
(ml) 
Theophylline 
(mg) 
Ethylcellulose 
(mg) 
Poly            
(ε-caprolactone) 
(mg) 
Methylene 
chloride 
(ml) 
Polyvinyl 
alcohol 
(0.1%) ml 
F4 
F5 
F6 
0.4:1 
0.6:1 
0.8:1 
1 
1 
1 
100 
150 
200 
125 
125 
125 
125 
125 
125 
5 
5 
5 
40 
40 
40 
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20 mA). The scanning rate was 2˚ /min over a 
range of 20-60˚ and with an interval of 0.02˚. 
 
Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry (DSC) plots 
were obtained, using Dynamic DSC (DSC 60, 
Shimadzu, Japan). An empty pin-holed 
aluminum pan was used as a reference. Both 
the reference pan and the sample pan were 
allowed to equilibrate isothermally for 5 min 
at 0 ˚C.  In  an  open  aluminum  pan  under  a          
10 ml/min stream of nitrogen purge, samples 
of 5 mg were heated from room temperature to 
300 ˚C at a heating rate of 10˚C/min. 
 
In vitro release studies  
Microparticles 
Theophylline dissolution patterns from 
microparticles were obtained under sinking 
conditions. USP rotating basket method was 
used for all microsphere formulations. A set 
amount of microspheres (100, 150 and 200 mg 
drug) was added to 900 ml dissolution medium 
(pH 1.2 HCl solution), preheated and maintained 
at 37±1 ˚C in a water bath, then stirred at 100 
rpm. Aliquots (5 ml) of the solution were 
withdrawn at appropriate intervals (0.25, 0.5, 
0.45, 1, 2, 3, 4, 5, 6, 8, 24 hr) through a 0.45 µm 
filter and replaced with an equal volume of fresh 
test fluid to keep the volume constant. After 2 hr, 
17 ml of 0.2 M phosphate buffer stock, pre-
equilibrated at 37 ˚C, were added to the 
dissolution vessel. The pH was immediately 
adjusted, if necessary, with 0.2 N HCl or 0.2 N 
NaOH to pH 7.4. Samples were suitably diluted 
with the same fluid, and drug concentration was 
measured by UV analysis at 207.6 nm (for acidic 
medium) or 208 nm (for alkaline buffer). 
Each experiment was performed in duplicate and 
a close reproducibility was attained.  
 
Nanoparticles and composite microparticles 
Nanoparticles or freez dried composite 
microparticles containing 100, 150 and 200 mg 
were suspended in 20 ml of phosphate buffer 
(pH 7.4). The suspension was stirred (200 rpm) 
at 37 °C into a water bath. Then 1 ml of 
suspension was withdrawn at appropriate 
intervals (0.25, 0.5, 0.45, 1, 2, 3, 4, 5, 6, 8, 24 hr) 
and, each sample was centrifuged at 42,000×g 
for 10 min. The filtrate (theophylline) was 
replaced by 1 ml of fresh buffer. The amount of 
theophylline in the release medium was 
determined by UV at 208 nm (8).  
 
Statistical analysis 
Results were evaluated using a one-way 
ANOVA (SPSS version 14), where P< 0.05 was 
taken to represent a statistically significant 
difference (23). 
 
Results 
A W/O/W multiple emulsion solvent 
evaporation/extraction method is mostly used for 
the encapsulation of water-soluble drug and 
therefore, was the method of choice for the 
water-soluble theophylline drug. In 
microparticles prepared by extraction method, 
the amount of drug entrapped in microspheres 
was lower than the theoretical value. In all 
formulations, the mean amount of drug 
entrapped increased from 0.4:1 to 0.8:1, the 
production yield increased (P< 0.05). Size of 
microspheres increased with an increase in the 
drug concentration (P< 0.05) (Table 3).  
 
Table 3. Effect of drug: polymer ratios on drug loading efficiencies, production yield s and particle sizes of theophylline 
microparticles, nanoparticles and composite microparticles.  
Process 
variable 
Formulation 
code 
Polymer/
drug ratio 
 
Production   
yield (%±SD) 
Theoretical drug 
content (%) 
Mean drug 
entrapped 
(%±SD) 
Drug loading 
efficiency 
(%±SD) 
Mean particle 
size (µm±SD) 
Microparticle 
F1 
F2 
F3 
0.4:1 
0.6:1 
0.8:1 
39.06±2.11 
41.20±3.14 
47.79±2.19 
28.57 
37.50 
44.44 
22.67±3.75 
35.32±2.51 
42.61±1.38 
79.24±3.56 
94.31±8.45 
95.88±7.06 
18.29±0.31 
19.48±0.42 
26.44±0.31 
 Nanoparticle 
F4 
F5 
F6 
0.4:1 
0.6:1 
0.8:1 
40.85±7.21 
3.46±41.25 
5.32±45.91 
28.57 
37.50 
44.44 
28.3±3.11 
37.5±5.15 
43.68±3.35 
99.05±7.18 
99.07±5.46 
98.29±6.32 
0.756±0.16 
0.857±0.253 
0.959±0.29 
Composite 
microparticle 
F7 
F8 
F9 
0.2:1 
0.3:1 
0.4:1 
36.67±3.02 
36.12±4.58 
35.48±5.08 
16.67 
23.08 
28.57 
16.47±1.21 
22.47±1.48 
27.15±1.27 
98.80±5.23 
97.36±6.43 
95.03±8.12 
8.69±0.29 
17.47±0.671 
17.70±0.59  
Mitra Jelvehgari et al 
 Iran J Basic Med Sci, Vol. 13, No. 3, Summer 2010    90 
i
h
g
f
e
d
c
b
a
A volume-based size distribution of drug, 
polymer, and drug in prepared nanoparticles 
and composite microparticles was near to the 
theoretical value, as the drug loading 
efficiency is almost 100%. As the ratio of drug 
to polymer increased the amount of free drug 
lost decreased (Table 3) so that at the ratio of 
drug  to  polymer  0.8:1  the  amount  of                 
drug entrapment was 42.61% which was very 
close to the theoretical value (44.44%). 
Generally,  increasing  the  drug-polymer           
ratio  increased  the  production  yield,  when          
the ratio of drug–polymer loaded 
microparticles and nanoparticles indicated a 
log-probability distribution. Mean particle size 
of original theophylline and ethylcellulose was 
51.206±0.474  µm and 2.53±0.179 µm, 
respectively. Mean particle size of F3  was 
26.44±0.31  µm.  The  data  describing                  
the particle sizes of the microspheres are given 
in Tables 3. As it can be seen, the sizes of 
particles were increased with an increase in the 
amount of the drug. The zeta potential of three 
nanosphere  formulations,  theophylline                
(-16.5 mV), ethylcellulose (-13.9 mV) and 
poly (ε-caprolactone) (+36 mV) are shown in 
Table 4. Blank nanoparticles had negative 
charge.  
Drug-loaded nanoparticles indicated a 
positive charge, because poly (ε-caprolactone) 
was a polycationic polymer and changed the 
charge of nanoparticles. The endothermic peak 
of  the  pure  drug  was  observed  at  about        
271.41  °C (Figure 1) and ethylcellulose 
showed an amorphous state. Indeed, in the 
thermogram of the nanoparticles containing 
poly (ε-caprolactone), there was endothermic 
peak at 59.12 ˚C. However, in the thermogram 
of the microparticles (simple and composite) 
and nanoparticles there was endothermic peak 
of the drug melting, but in the thermogram of 
the composite microparticles, there was no 
endothermic peak of the poly (ε-caprolactone). 
In the thermogram of nanoparticles, there was 
no endometric peak of theophylline. The X-ray 
diffraction patterns of pure drug and poly (ε-
caprolactone) showed that the pure drug and 
poly (ε-caprolactone) are crystalline in nature 
(Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.  DSC  thermograms    of  a)  theophylline;              
b) ethylcellulose; c) poly (ε-caprolactone); d) simple 
microparticles; e) blank microparticles; f) nanoparticles; 
g) blank nanoparticles; h) composite microparticles; i) 
blank composite microparticles.  
   
 
Figure  2.  X-ray  diffractions  of  a)  theophylline;                   
b) ethylcellulose; c) blank microparticles; d) simple 
microparticles;  e)  blank  nanoparticles;  f)  poly                   
(ε-caprolactone); g) nanoparticles; h) blank composite 
microparticles; i) composite microparticles. 
 
Table 4. Effect of drug to polymer ratio of theophylline 
on the zeta potential of the nanoparticles. 
 
Samples                                    Zeta potential (mV) 
Theophylline                                        -16.5 
Ethylcellulose                                      -13.9 
Poly (є-caprolactone)                            +36 
F4                                                          -11.4 
F5                                                          -12.3 
F6                                                          -12.5 
Blank nanoparticle                              - 4.8  
Poly (ε-caprolactone) Nanoparticles-in-microparticles 
 Iran J Basic Med Sci, Vol. 13, No. 3, Summer 2010     91
0
20
40
60
80
0123
C
u m
u l a t i v e   %
  R e l e
a s e
Time (h our)
0
20
40
60
80
100
048 1 2 1 6 2 0 2 4
C u m
u l a t i v e   %
  R e l e a s e
Time (hour)
Composite microparticle 100 mg Composite micropar cle 150 mg"
Composite mi cropar cle 200 mg"
0
5
10
15
0123
C
u m
u l a t i v e   %
  R e
l e a s e
Time (h our)
0
20
40
60
80
100
0 4 8 12 16 20 24
C u m
u l a t i v e   %
  R e l e a s e
Time (h our)
Mic ropa rtic le Theo 100 mg Mi cropar cle Theo 150 mg Micropar cle Theo 200 mg
0
10
20
30
40
50
048 1 2 1 6 2 0 2 4
C u m
u l a t i v e   %
  R e l e a s e
Time (h our)
Nanop ar cle 100 mg Nanopar cle 150 mg Nanoparticle 200 mg
0
5
10
15
20
0123
C u m
u l a t i v e
  %
  R e
l e a s e
Tim e (ho ur)
A
B
C
In vitro release studies 
The  in vitro release of theophylline from 
microparticles and nanoparticles exhibited an 
initial burst effect, which may be due to the 
presence of some drug particles on the surface 
of the microparticles and nanoparticles. The 
release profiles are illustrated in Figure 3. 
Theophylline always shows an expected 
increase in dissolution after the change of pH 
from 1.2 to 7.4. For microparticles, dissolution 
of theophylline at pH 7.4 strongly showed an 
initial burst effect. The results indicated that 
some factors such as a drug-polymer ratio 
governed the drug release from these 
microparticles. The results indicated that some 
factors such as a drug-polymer ratio governed 
the drug release from these microparticles. 
Drug release rates were decreased with 
increasing amounts of theophylline in the 
formulation (Figure 3A). PCL-loaded 
nanoparticles of each formulation displayed an 
immediate and important initial drug release in 
the  first  15  min,  followed  by  duration  of          
20-35% release in 24 hr which was obtained   
(Figure 3B). The initial percentage of drug 
release and dissolution profiles was very 
different for all types of microparticles 
compared with nanoparticles, as shown in 
Figure 3C. However, composite microparticles 
tend to reduce the initial burst effect especially 
compared with microparticles prepared from 
ethylcellulose alone (simple microparticles). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cumulative percent release of theophylline from A) simple microspheres; B) nanoparticles; C) composite 
microparticles  prepared with different drug-to-polymer ratio. 
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Discussion  
Drug entrapped in microspheres indicated that 
some free drug crystals were lost in the 
process of encapsulation and lost the drug 
when immigrated to aqueous phase. The 
encapsulation efficiency of the drug was 
depended on the solubility of the drug in the 
solvent and continuous phase. A similar 
observation was reported by Youan et al (24). 
Important prerequisites for high encapsulation 
efficiencies by the W/O/W method are: (1) the 
insolubility of the drug in the external phase 
from the internal aqueous phase, and (2) the 
fine dispersion of the  aqueous drug solution 
into the  organic  to  form  a  W/O  emulsion          
(25, 26). Theophylline is insoluble in organic 
solvents used to dissolve the polymer 
(methylene chloride or ethyl acetate) and thus 
cannot partition from the internal into the 
external aqueous phase via diffusion through 
the organic polymer solution. In order to 
obtain a fine dispersion, the aqueous 
theophylline solution was added to the 
organic. The encapsulation efficiencies 
increased  from  about  30%  without  shaking        
to more than 90% (7). Despite the 
hydrosolubility of theophylline, which favors 
the leakage of the drug into the external 
aqueous phase, entrapment efficiencies were 
rather high. It is assumed that theophylline is 
localized at the interfaces (either internal water 
in oil or external oil in water). Therefore, a 
significant amount of drug is supposed to be 
adsorbed at the outer surface. With increasing 
theophylline concentration, there is a 
saturation of the outer surface. At that time, 
the drug will dissolve more in the aqueous 
core and the encapsulation efficiency will also 
consequently increase (8). In addition, the 
removal of the organic solvent under reduced 
pressure favors its fast evaporation followed 
by the polymer precipitation, thus reducing the 
migration of the drug to the external phase. 
Indeed, the faster the solvent evaporation is, 
the higher the encapsulation efficiency will be. 
One possible explanation could concern the 
increase of the internal phase viscosity due to 
the different theophylline concentrations 
studied which could reduce the leakage of the 
drug towards the external aqueous phase (8).     
The reason for increased production yield at 
high drug: polymer ratios could be due to 
decreased diffusion rate of solvent (ethyl acetate) 
from concentrated solutions into initial emulsion 
(Table 3). Size of microspheres can be attributed 
to the fact that with a higher diffusion rate of 
non-solvent to the polymer solution the smaller 
size of microcapsules is easily obtained (27, 28). 
It has already been reported that particle size was 
proportional to the viscosity of the dispersed 
phase (29-32). In fact viscosity of the dispersed 
phase was increased from F1 (0.4:1) to F3 
(0.8:1). When the viscosity of the dispersed 
phase of these formulations was investigated it 
was found that particle sizes of microparticles 
were directly proportional to the apparent 
viscosity of dispersed phase. The results showed 
that the apparent viscosities of the different drug: 
polymer ratios (0.4:1, 0.6:1 and 0.8:1) were 8, 14 
and 17 mPa.S (mega Pascal Second) 
respectively. When the dispersed phase with 
higher viscosity was poured into the dispersion 
medium, bigger droplets were formed with 
larger mean particle size.  
Addition of a cationic polymer could lead to 
the flocculation of yeast cells thus forming 
macroscopic flocs (33). Flocculation occurs by 
two main mechanisms (a) formation of 
macromolecular bridges between the particles, 
and (b) surface and charge reduction due to the 
adsorption of highly charged polyelectrolytes 
on oppositely charged particles (33). In other 
words, zeta potential is the potential difference 
between the dispersion medium and the 
stationary layer of fluid attached to the 
dispersed particle. A value of zeta potential 
(positive) could be taken as the arbitrary value 
that separates low-charged surfaces from 
highly-charged surfaces. The significance of 
zeta potential is that its value can be related to 
the stability of colloidal dispersion. The zeta 
potential indicates the degree of repulsion 
between adjacent, similarly charged particles 
in dispersion. For molecules and particles that 
are small enough, a high zeta potential will 
confer stability, i.e. the solution or dispersion 
will resist aggregation (22).  
The drug may have been dispersed in a 
crystalline or amorphous form or dissolved in 
the polymeric matrix during formation of the  
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microspheres. Any abrupt or drastic change in 
the thermal behavior of either the drug or 
polymer may indicate a possible drug-polymer 
interaction (34).  
However, endothermic peak of the drug 
melting of the microparticles (simple and 
composite) and nanoparticles, suggests the 
crystalline state of the drug in the polymeric 
matrix but in the thermogram of the composite 
microparticles, presenting the amorphous state 
of the poly (ε-caprolactone) in the composite 
microparticles (Figure 1) (35). The 
thermogram of nanoparticles, showed that 
drug had been dispersed in amorphous form in 
the polymeric matrix during formation of the 
nanoparticles (Figure 1). 
However, when they were incorporated into 
the polymeric matrix, the principal peaks of the 
drug existed or could be observed with less 
intensity. Figure 2 shows the amorphous state of 
the poly (ε-caprolactone) in the composite 
microparticles and confirms the results obtained 
from DSC. 
In most cases, a biphasic dissolution profile 
was observed at pH 7.4: the initial rapid drug 
leakage generally ended very early and for the 
remaining time, nearly linear behavior was 
observed. It showed that the first portion of the 
curves is due to theophylline dissolution, 
which starts immediately after the beginning 
of the test for the portion of drug on the 
surface of microparticles. After such a phase, 
two phenomena can combine in enhancing the 
diffusion of the remaining dispersed drug into 
the bulk phase as well as the formation of 
pores within the matrix due to the initial drug 
dissolution; particle wetting and swelling 
which enhances the permeability of the 
polymer to the drug (36) (Figure 3). As more 
drugs are released from the microparticles, 
more channels are probably produced, 
contributing to faster drug release rates. 
However, Figure 3A shows that the burst 
effect is lower when the theophylline to 
polymer ratio is 0.4:1 (F1) compared with 
0.8:1 (F3). In F3 formulation, an increase of the 
internal phase viscosity due to the different 
theophylline concentrations could reduce the 
leakage of the drug towards the external 
aqueous phase and decrease the burst effect 
and release rate (compare with F1 and F2). This 
immediate high burst release might be due to 
the small diameter of nanoparticles leading to 
a large exchange surface and probably to a 
more porous structure owing to the solvent 
evaporation method, favoring the release of 
the encapsulated drug (2, 8). Indeed, it has 
already been demonstrated that the slow 
precipitation of microparticles after solvent 
evaporation leads to more porous particles 
compared to the fast polymer precipitation 
obtained after solvent extraction (8, 15). 
Although not all of encapsulated drug was 
released in 24 hr, the dissolution test was 
limited to this time because the aim of this 
research was to demonstrate the influence of 
the encapsulation of nanoparticles within 
microparticles on the initial burst release. 
Moreover, the burst release could also be 
explained by the imperfect encapsulation of 
the drug inside nanoparticles, resulting from 
the unstable nature of the emulsion droplets 
during the solvent removal step. 
The incomplete release of the drug from 
each formulation could result from the rather 
short time of the release study. This initial 
release was followed by a rather stable plateau 
between 2 and 6 hr. The interactions between 
theophylline and the polymers may slow down 
the drug release or hamper its complete 
dissolution. Our results are consistent with 
Okada et al who reported an increase in Tg of 
PLGA microspheres (as observed with EC and 
PLGA nanoparticles) with increasing basic 
drug content, implying an incomplete and 
slower drug release (37). Although the 
increase in Tg correlated with a decrease in 
chain mobility was predominant (made the 
matrix more rigid). 
Usually when there are strong interactions 
between the drug and the polymer, the Tg is 
significantly decreased. In addition, although 
the melting temperature of the drug decreased 
significantly after encapsulation, its crystalline 
state was maintained, probably as very small 
and unstable crystals. It has to be noted that in 
the order studies, the melting temperature of 
the encapsulated drug was totally disappearing 
from the DSC runs, meaning a transformation 
to an amorphous state.  
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Reduction in the initial burst effect can be 
explained not only by the rather hydrophilic 
properties of theophylline which favors it’s 
diffusion towards the surrounding aqueous 
media, but also by high encapsulation ratio of 
PCL nanoparticles (8, 17). Encapsulation of 
nanoparticles into microparticles also had a 
strong effect on the dissolution profiles. The 
presence of ethylcellulose in the matrix of 
microparticles conferred a slower and more 
progressive release of theophylline during the 
time of the experiment (1, 8).  This is indeed, 
due to the slow diffusion of water into the 
lipophilic ethylcellulose matrix (2, 8). 
However, in terms of burst release reduction 
there is a difference between simple and 
composite microparticles (Table 5). When 
PCL nanoparticles were encapsulated into the 
microparticles (Figure 3C), there was a large 
decrease in burst release again (0.23-1.16%), 
this decrease is much more marked (P< 0.05). 
Therefore, the advantage of encapsulating 
nanoparticles in microparticles (composite 
microparticles) has been definitely demonstrated 
for the hydrophilic drug (8, 17). The in vitro 
release profiles were fitted on  various
 
 
Table 5. Mean of theophylline released after 0.25 hr and 24 hr from simple microparticles, nanoparticles and composite 
microparticles. 
 
 
 
 
 
 
 
 
 
 
            
 
 
 
a: Amount of drug release after 0.25 hr, b: amount of drug release after 24 hr. 
 
 
Table 6.  Parameters of the in vitro release data fitted to various release kinetic models for nanoparticles and 
composite microparticles.   
bQ24 
aQ0.25  Formulation 
4.05±81.10  0.44±44.32  F1 
3.40±86.84  0.14±16.31  F2 
2.55±89.47  0.03±12.39  F3 
0.36±33.32  0.04±14.54  F4 
1.82±24.15  0.05±10.64  F5 
1.77±21.18  0.14±8.33  F6 
0.82±20.31  0.08±1.16  F7 
0.54±21.87  0.02±0.4  F8 
1.98±22.01  0.02±0.23  F9 
F9  F8  F7  F6  F5  F4  F3  F2  F1  Order 
0.0002  0.0001  0.0001  0.0001  0.0002  0.0003  0.0005  0.0005  0.0003  K 
0.6233  0.5852  0.4336  0.6525  0.6075  0.5811  0.6216  0.5343  0.6159  RSQ 
629.9116  647.9950  901.9522  848.0612  513.8522  499.8675  841.2354  892.4038  982.3664  D (SS)% 
Zero 
f=kt  
0.0002  0.0002  0.0001  0.0001  0.0002  0.0003  0.0015  0.0022  0.0008  K 
0.6335  0.5988  0.4535  0.6610  0.6197  0.5919  0.8636  0.8983  0.7287  RSQ 
604.6704  628.5015  879.9270  818.7032  513.0387  556.7263  569.0389  529.4631  822.1482  D (SS)%  
First 
Ln (1-f)=kt 
0.8992  0.9765  0.5275  0.3587  1.0642  1.1543  0.5905  0.5044  0.0575  B 
0.0007  0.0005  0.0078  0.0170  0.0002  0.0002  0.0230  0.0451  0.3790  K 
0.8324  0.8109  0.7257  0.8973  0.8556  0.8737  0.9827  0.9282  0.9778  RSQ 
566.7799  674.4713  419.5801  143.1441  637.9919  623.2251  51.4170  41.9376  2.4625  D (SS)%  
Peppas 
Lnf=lnk+blnt  
 
0.0072  0.0073  0.0052  0.0054  0.0088  0.0125  0.0251  0.0250  0.0126  K 
0.8121  0.8033  0.6940  0.8149  0.7919  0.7652  0.8570  0.7878  0.8361  RSQ 
1457.8144  1762.7658  530.9801  372.2460  3177.4460  4018.7570  271.2409  450.3528  791.4635  D (SS)%  
Higuchi 
f=kt 
0.5  
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kinetic models, in order to find out the 
mechanism of drug release (38, 39). The fit 
parameters to Higuchi, first-order, Peppas and 
zero-order equations are given in Table 6. The 
rate constants were calculated from the slope 
of the respective plots. High correlation was 
observed for the Peppas model. The data 
obtained were also put in Korsemeyer-Peppas 
model, in order to find out then value, which 
described  the  drug  release  mechanism.  The        
n value of composite microspheres with 
different drug to polymer ratio was between 
0< n<0.5, indicating that the mechanism of the 
drug release was diffusion controlled 
 
Conclusion 
More generally, the differences observed with 
the composite microparticles might be 
explained by the heterogeneous composition 
of polymeric matrix. A fast rate of solvent 
removal can also contribute to a heterogeneous 
distribution of drug within the internal phase 
as it hardens which would further explain the 
biphasic release profile. Indeed, in order to be 
released into the external dissolution medium, 
theophylline has to diffuse first through the 
PCL nanoparticles followed by another 
diffusion step through the ethylcellulose. The 
diffusion pathway takes longer due to the 
hydrophobicity of this polymer. The overall 
dissolution profiles show the potential of 
composite microparticles to dramatically 
change the burst effect and release profile of 
drug in vitro. 
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